drugset / Trial / NCT01285570

Ulimorelin Study of Efficacy and Safety (ULISES 007)

NCT01285570

Phase 3 Completed 332 enrolled Tranzyme, Inc. Norgine · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

Post-operative administration of ulimorelin is expected to reduce time to recovery of Gastrointestinal (GI) function in patients who have undergone partial large bowel resection.

Timeline

Start
2011-01
Primary completion
2012-01
Completion
2012-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Ulimorelin Small molecule 160 ug/kg Intravenous
Subject Ulimorelin Small molecule 480 ug/kg Intravenous